Current Medicinal Chemistry Journal Impact Factor & Information

Publisher: Bentham Science Publishers

Journal description

Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each bi-weekly issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.

Current impact factor: 3.85

Impact Factor Rankings

2015 Impact Factor Available summer 2015
2013 / 2014 Impact Factor 3.715
2012 Impact Factor 4.07
2011 Impact Factor 4.859
2010 Impact Factor 4.63
2009 Impact Factor 4.708
2008 Impact Factor 4.823
2007 Impact Factor 4.944
2006 Impact Factor 5.207
2005 Impact Factor 4.904
2004 Impact Factor 4.382
2003 Impact Factor 4.409
2002 Impact Factor 4.966
2001 Impact Factor 5.76
2000 Impact Factor 4.909
1999 Impact Factor 3
1998 Impact Factor 1.522
1997 Impact Factor 2.269

Impact factor over time

Impact factor
Year

Additional details

5-year impact 4.47
Cited half-life 5.50
Immediacy index 0.63
Eigenfactor 0.03
Article influence 1.19
Website Current Medicinal Chemistry website
Other titles Current medicinal chemistry (Online)
ISSN 1875-533X
OCLC 55201153
Material type Document, Periodical, Internet resource
Document type Internet Resource, Computer File, Journal / Magazine / Newspaper

Publisher details

Bentham Science Publishers

  • Pre-print
    • Author can archive a pre-print version
  • Post-print
    • Author cannot archive a post-print version
  • Restrictions
    • 12 months embargo
  • Conditions
    • Author's pre-print on author's personal website, institutional repository and open access repository
    • Author's post-print on author's personal website, institutional repository, open access repository, PubMed Central and arXiv
    • Non-Commercial
    • Published source must be acknowledged
    • Must link to journal home page with DOI
    • Publisher's version/PDF cannot be used
  • Classification
    ​ yellow

Publications in this journal

  • [Show abstract] [Hide abstract]
    ABSTRACT: Peripheral artery disease (PAD) is an inflammatory disease caused by atherosclerosis. It has been demonstrated that PAD is related to chronic inflammation. While conventional risk factors lead to the pathogenesis and progression of PAD, the role of novel inflammatory biomarkers in relation to PAD is being increasingly recognized. The novel biomarkers for PAD may allow for earlier screening and detection, suppression of disease progression, and development of new therapeutic approaches. In this review, inflammatory biomarkers that should be contributory to diagnosis, prognosis, and avenues for therapeutic challenges in PAD are summarized.
    Current Medicinal Chemistry 06/2015;
  • [Show abstract] [Hide abstract]
    ABSTRACT: Inflammation plays a critical role in the atherosclerotic process in various vascular beds, starting from endothelial dysfunction and counting all stages of plaque development. The significant contribution of inflammation in the initiation and progression of atherosclerosis has been documented over many years but its contribution to the development of other cardiovascular disease remains unclear. Inflammatory process constitutes a basic part of pathogenic cascade of aortic diseases including those of aortic valve stenosis and aortic aneurysms. Thus, both of these entities are related with high rates of morbidity and mortality. Therefore, the need to detect and investigate indices representative of inflammation that will be easily measured and may reflect the process of these diseases, is mandatory. However, such biomarkers for aortic diseases that could have a significant prognostic value on survival via the early identification of high risk patients, in general remain few. Therefore, the illumination of role of such biomarkers, will facilitate the understanding of the mechanisms in molecular and/or cellular level that are responsible for the creation of aortic disease such an approach may provide a pathophysiological basis for early diagnosis.
    Current Medicinal Chemistry 06/2015;
  • [Show abstract] [Hide abstract]
    ABSTRACT: In the current context of antiviral drug development, which has been traditionally dominated by herpesviruses, human immunodeficiency virus (HIV) and hepatitis C virus (HCV), a new viral target has been recently gained unforeseen attention, Ebola virus. Ten nucleoside analogues, or categories thereof, are reviewed for their therapeutic potential as antiviral drugs: (i) BCX4430, a C-nucleoside; (ii) 4'-azido-, 4'-cyano-, and 4'-ethynyl derivatives; (iii) 4'-thionucleosides; (iv) cordycepin (3'-deoxyadeosine); (v) pyrazofurin, another C-nucleoside; (vi) neplanocin A analogues; (vii) EICAR, a ribavirin analogue; (viii) GR-92938X, a double carboxamide; (ix) sofosbuvir (Solvaldi®), a 2'-C-methylnucleoside; and (x) favipiravir (T-705), a pyrazine analogue.
    Current Medicinal Chemistry 06/2015;
  • [Show abstract] [Hide abstract]
    ABSTRACT: Asymmetric dimethylarginine (ADMA) is a competitive endogenous inhibitor of nitric oxide synthase with a key role in the pathophysiology of endothelial dysfunction, in the progression of atherosclerosis and in cardiovascular diseases. Statins, renin-angiotensin-aldosterone system inhibitors, blood glucose lowering agents, insulin sensitizers, beta-blockers, estrogen replacement therapy, antioxidants, complex B vitamins, L-arginine and acetylsalicylic acid have been evaluated for their ability to reduce ADMA levels or inhibit its actions. Despite the major beneficial effects of these agents in cardiovascular disease, research has shown that their favorable actions are only partially mediated by reducing ADMA levels or by bypassing its effect in nitric oxide synthesis. Novel therapeutic approaches targeting selectively ADMA are encouraging, but have only been tested in vitro or in animal studies and further research is needed in order to conclude on how therapeutic strategies modulating ADMA actions can affect atherosclerosis progression and cardiovascular diseases.
    Current Medicinal Chemistry 06/2015;
  • [Show abstract] [Hide abstract]
    ABSTRACT: Diabetic Nephropathy (DN) is believed to be a major microvascular complication of diabetes. The hallmark of DN includes deposition of Extracellular Matrix (ECM) proteins, such as, collagen, laminin and fibronectin in the mesangium and renal tubulo-interstitium of the glomerulus and basement membranes. Such an increased expression of ECM leads to glomerular and tubular basement membranes thickening and increase of mesangial matrix, ultimately resulting in glomerulosclerosis and tubulointerstitial fibrosis. The characteristic morphologic glomerular mesangial lesion has been described as Kimmelstiel-Wilson nodule, and the process at times is referred to as diabetic nodular glomerulosclerosis. Thus, the accumulation of ECM proteins plays a critical role in the development of DN. The relevant mechanism(s) involved in the increased ECM expression and their regulation in the kidney in diabetic state has been extensively investigated and documented in the literature. Nevertheless, there are certain other mechanisms that may yet be conclusively defined. Recent studies demonstrated that some of the new signaling pathways or molecules including, Notch, Wnt, mTOR, TLRs and small GTPase may play a pivotal role in the modulation of ECM regulation and expression in DN. Such modulation could be operational for instance Notch though Notch1/Jagged1 signaling, Wnt by Wnt/β-catenin pathway and mTOR via PI3-K/Akt/mTOR signaling pathways. All these pathways may be critical in the modulation of ECM expression and tubulo-interstitial fibrosis. In addition, TLRs, mainly the TLR2 and TLR4, by TLR2-dependent and TGF-β-dependent conduits, may modulate ECM expression and generate a fibrogenic response. Small GTPase like Rho, Ras and Rab family by targeting relevant genes may also influence the accumulation of ECM proteins and renal fibrosis in hyperglycemic states. This review summarizes the recent information about the role and mechanisms by which these molecules and signaling pathways regulate ECM synthesis and its expression in high glucose ambience in vitro and in vivo states. The understanding of such signaling pathways and the molecules that influence expression, secretion and amassing of ECM may aid in developing strategies for the amelioration of diabetic nephropathy.
    Current Medicinal Chemistry 06/2015;
  • [Show abstract] [Hide abstract]
    ABSTRACT: L-3,4-Dihydroxyphenylalanine [2-amino-3-(3,4-dihydroxyphenyl) propanoic acid L-DOPA is a natural constituent of animal and plant tissue derived from post-translational modification of the amino acid tyrosine. DOPA is modified during metabolism to catecholamine neurotransmitters, noradrenaline and adrenaline, which are characterized by different biological activities. DOPA has been the first drug of choice in the therapy of Parkinson's disease that is a progressive neurodegenerative disorder involving the loss of dopaminergic neurons of the substantia nigra pars compacta. The social and economic impact of these diseases is very high due to the progressive aging of the population. DOPA-containing peptides (DOPA-Pep) also show important biological and pharmacological activities. For example, DOPA analogues of the alpha-factor interact with models of the G protein-coupled receptor, inhibit the oxidation of low-density lipoproteins, and are used for improving DOPA absorption in long-term treatment of Parkinson's disease and as skin moisturizer in cosmetic compositions. Moreover, DOPA residues in proteins provide reactive tools for the preparation of adhesives and coatings materials. Usually, DOPA-Pep are prepared by traditional liquid or solid state procedures starting from simple amino acids. Recently, selective side-chain modifications of pre-formed peptides have been also reported both for linear and branched peptides. Here, we describe recent advances in the synthesis of DOPA and DOPA-peptidomimetics and their biological and pharmacological activities, focusing the attention on new synthetic procedures and biological mechanism of actions.
    Current Medicinal Chemistry 06/2015;
  • [Show abstract] [Hide abstract]
    ABSTRACT: Heterocyclic N-oxides have emerged as potent compounds with anticancer, antibacterial, antihypertensive, antiparasitic, anti-HIV, anti-inflammatory, herbicidal, neuroprotective, and procognitive activities. The N-oxide motif has been successfully employed in a number of recent drug development projects. This review surveys the emergence of this scaffold in the mainstream medicinal chemistry with a focus on the discovery of the heterocyclic N-oxide drugs, N-oxide-specific mechanisms of action, drug-receptor interactions and synthetic avenues to these compounds. As the first review on this subject that covers the developments since 1950s to date, it is expected that it will inspire wider implementation of the heterocyclic N-oxide motif in the rational design of new medicinal agents.
    Current Medicinal Chemistry 06/2015;
  • [Show abstract] [Hide abstract]
    ABSTRACT: Estrogen receptors mediate numerous favorable effects on cells and molecules implicated in vascular inflammation and atherogenetic process. However, harmful effects have also been suggested. Actually, premenopausal women have a significantly lower risk for cardiovascular disease comparing to postmenopausal women or age matched males while the incidence of cardiovascular disease is greater in postmenopausal than premenopausal women of the same age. The balance of expression between the various ER subtypes may play an important role in the paradoxical characterization of estrogens as both beneficial and harmful. The activation of the newly discovered estrogen receptor GPR30 appears to be of great potential as therapeutic target in coronary heart disease, though the signaling mechanisms mediated GPR30 function still have not fully elucidated. Further research into vascular ERs is of great interest in order to promote the development of specific ER-agonists with improved benefit/risk ratio. The aim of this review is to summarize the involvement of each estrogen receptor subtype in the direct estrogen effects in different cellular components that participate in the atherosclerotic inflammatory process. We hope this knowledge will shed some light to the reasons for this paradoxical characterization of estrogens as both beneficial and harmful, and advance research in the development of specific ER-agonists with improved benefit/risk ratio.
    Current Medicinal Chemistry 06/2015;
  • Current Medicinal Chemistry 06/2015;
  • [Show abstract] [Hide abstract]
    ABSTRACT: Schizophrenia is a complex neuropsychiatric disorder with limited treatment options and highly debilitating symptoms, leading to poor personal, social, and occupational outcomes for an afflicted individual. Our current understanding of schizophrenia suggests that dopaminergic and glutamatergic systems have a significant role in the pathogenesis of the disease. Kynurenic acid, an endogenous glutamate antagonist, is found in elevated concentrations in the prefrontal cortex and cerebrospinal fluid of patients with schizophrenia, and this affects neurotransmitter release in a similar manner to previously observed psychotomimetic agents, such as phencyclidine, underlining the molecular basis to its link in schizophrenia pathophysiology. Kynurenic acid is a breakdown product of tryptophan degradation, through a transamination process mediated by kynurenine aminotransferase (KAT) enzymes. There are four KAT homologues reported, all of which are pyridoxal-5'-phosphate-dependent enzymes. All four KAT isoforms have been analysed structurally and biochemically, however the most extensive research is on KAT-I and KAT-II. These two enzymes have been targeted in structure-based drug design as a means of normalising raised kynurenic acid levels. The most potent KAT-I inhibitors and KAT-II inhibitors include phenylhydrazone hexanoic acid derivatives and a pyrazole series of compounds, respectively. KAT inhibitors have been shown to be effective in reducing kynurenic acid production, with accompanying changes in neurotransmitter release and pro-cognitive effects seen in animal studies. This review will discuss the characteristics pertaining to the different KAT isoforms, and will highlight the development of significant KAT inhibitors. KAT inhibitors have great potential for therapeutic application and represent a novel way in treating schizophrenia.
    Current Medicinal Chemistry 06/2015;
  • [Show abstract] [Hide abstract]
    ABSTRACT: Antimicrobial resistance is one of the most serious public health problems. This is of particular concern when bacteria become resistant to various antimicrobial agents simultaneously and when they form biofilms. Consequently, therapeutic options for the treatment of infections have become limited, leading frequently to recurrent infections, treatment failure and increase of morbidity and mortality. Both, persistence and spread of antibiotic resistance, in combination with decreased effectiveness and increased toxicity of current antibiotics have emphasized the urgent need to search alternative sources of antimicrobial substances. Plants are recognized as a source of unexplored chemical structures with high therapeutic potential, including antimicrobial activity against clinically important microorganisms. Additionally, phytochemicals (plant secondary metabolites) present several advantages over synthetic molecules, including green status and different mechanisms of action from antibiotics which could help to overcome the resistance problem. In this study, an overview of the main classes of phytochemicals with antimicrobial properties and their mode of action is presented. A revision about the application of phytochemicals for biofilm prevention and control is also done. Moreover, the use of phytochemicals as scaffolds of new functional molecules to expand the antibiotics pipeline is reviewed.
    Current Medicinal Chemistry 05/2015;
  • Current Medicinal Chemistry 05/2015;
  • [Show abstract] [Hide abstract]
    ABSTRACT: In the last twenty years, numerous reports provided solid evidence on the involvement of the mitochondrial permeability transition pore (PTP) in myocardial injury caused by ischemia and reperfusion. Indeed, significant cardioprotection is obtained by reducing the open probability of the PTP. This goal has been achieved by pharmacological and genetic interventions aimed at inhibiting cyclophilin D (CyPD), a regulatory protein that favors PTP opening. On the other hand, CyPD inhibition or deletion has been shown to worsen remodeling of the hypertrophic heart, an adverse outcome that must find an explanation within PTP modulation by CyPD. In this review, recent advancements in defining the molecular identity of the PTP are analyzed in relation to its pathophysiological functions and pharmacological modulation. In this respect, advantages and limitations of compounds targeting CyPD are discussed with the analysis of novel PTP inhibitors that do not interact with CyPD.
    Current Medicinal Chemistry 05/2015;
  • [Show abstract] [Hide abstract]
    ABSTRACT: During past two decades, plant-derived bioactive compounds have been reported as novel therapeutic agents for prevention and/or mitigation of different human diseases such as cancer, inflammation, cardiovascular and neurodegenerative diseases. Hesperidin is known as one of the most common and bioactive constituent of citrus species which possess multiple health-promotion effects. A plethora of scientific literature reported that hesperidin possess in-vitro and in-vivo anticancer activities. In addition, there are numerous scientific evidences regarding the molecular mechanisms of anticancer activities of hesperidin and its aglycone, hesperetin. Nevertheless, a comprehensive review of the molecular mechanisms underlying the anticancer effects of hesperidin has not appeared. Therefore, in this work we present a critical review of the available literature regarding the molecular mechanisms of the anticancer effects of hesperidin and its aglycone, hesperetin.
    Current Medicinal Chemistry 05/2015;
  • [Show abstract] [Hide abstract]
    ABSTRACT: Cyathane diterpenoids, occurring exclusively in higher basidiomycete (mushrooms), represent a structurally diverse class of natural products based on a characteristic 5-6-7 tricyclic carbon scaffold, including 105 members reported to date. These compounds show a diverse range of biological activities, such as antimicrobial, anti-MRSA, agonistic toward the kappa-opioid receptor, anti-inflammatory, anti-proliferative and nerve growth factor (NGF)-like properties. The present review focuses on the structure diversity, structure elucidation and biological studies of these compounds, including mechanisms of actions and structure-activity relationships (SARs). In addition, new progress in chemical synthesis of cyathane diterpenoids is discussed.
    Current Medicinal Chemistry 05/2015;
  • [Show abstract] [Hide abstract]
    ABSTRACT: HER2 receptor, for its involvement in tumor genesis, has been largely studied as topic in cancer research. In particular, the employment of trastuzumab (Herceptin), a humanized anti- HER2 antibody, in the therapy against the breast cancer showed several clinical benefits. Moreover, for its accessible extracellular domain, this receptor is considered an ideal target to deliver anticancer drugs for the receptor-mediated anticancer therapy. By now, monoclonal antibody and its fragments, affibody, and some peptides have been employed as targeting agents in order to deliver various drugs to HER2 positive tumor cells. In particular, the ability to perform a fast and reliable screening of a large number of peptide molecules would make possible the selection of highly specific compounds to the receptor target. In this regard, the availability of preparing a simplified synthetic model which is a good mimetic of the receptor target and can be used in a reliable screenings method of ligands would be of a strategic importance for the development of selective HER2-targeting peptide molecules. Herein, we illustrate the importance of HER2-targeted anticancer therapies. We also report on a synthetic and effective mimetic of the receptor, which reveled to be a useful tool for the selection of specific HER2 ligands.
    Current Medicinal Chemistry 05/2015;
  • [Show abstract] [Hide abstract]
    ABSTRACT: Hyperlipidemia is characterized by abnormally increased plasma of any or all lipids and /or lipoproteins and is a well-known risk factor for the development of atherosclerosis. The role of inflammation in the development and progression of atherosclerosis and consequently on cardiovascular diseases is well established. Systemic inflammation and immune system play a central role in atherogenesis. Multiple levels of evidence from experimental models and histopathologic assessment of tissues to systemic biomarkers and epidemiologic or clinical associations have revealed that the inflammation is a key mechanism in the destabilization of atherosclerosis and lead to clinical events. Several inflammatory markers such as C-reactive protein, interleukin 6 and Interleukin 1β, tumor necrosis factor-alpha, pentraxin3, serum amyloid A, sCD40, adhesion molecules, monocyte chemo-attractant protein-1, sEndoglin, PAPP-A, chemokine 16, insulin like growth factor, lipoprotein -associated phospholipase A2 and galectin 3 are associated with lipids level and the process of atherosclerosis. Their role in atherogenesis in not well established for all of them. As the atheromatosis is the major cause of death in the world, in future studies it will be important to determine whether these markers play a causal role in this process in order to have a better prognosis, diagnosis and understanding of this disorder. The aim in this review is to study the literature on the novel inflammation marker of hyperlipidemia according to their clinical implications.
    Current Medicinal Chemistry 05/2015;